14529-54-5

Usage

Uses

Used in Pharmaceutical Industry:
3,5-DIBROMO-1-METHYL-1H-PYRIDIN-2-ONE is used as a building block for the synthesis of various drugs and biologically active compounds due to its unique chemical structure and properties.
Used in Crop Protection Products:
3,5-DIBROMO-1-METHYL-1H-PYRIDIN-2-ONE is used as an active ingredient in the development of new crop protection products, leveraging its antimicrobial, antifungal, and herbicidal properties to protect crops from various pests and diseases.
Used in Antitumor and Anti-inflammatory Drug Development:
3,5-DIBROMO-1-METHYL-1H-PYRIDIN-2-ONE is used as a potential candidate for the development of new drugs with antitumor and anti-inflammatory activities, as it has shown promise in preliminary investigations.
Safety Precautions:
It is important to handle 3,5-DIBROMO-1-METHYL-1H-PYRIDIN-2-ONE with care, as it is potentially hazardous. Proper safety precautions and handling procedures should be followed to minimize risks associated with its use.

InChI:InChI=1/C6H5Br2NO/c1-9-3-4(7)2-5(8)6(9)10/h2-3H,1H3

Upstream product

• 876489-92-8 (1-methyl-6-oxo-1,6-dihydro-[3]pyridyl)-arsonic acid 
• 1121-27-3 1-methyl-2-pyridone hydrobromide 
• 694-85-9 1-methyl-2-pyridone 
• 13472-81-6 3,5-dibromo-2-hydroxypyridine 
• 80-48-8 methyl p-toluene sulfonate 
• 142-08-5 2-hydroxypyridin 
• 74-88-4 methyl iodide 
• 13472-81-6 3,5-dibromo-2-hydroxypyridine 
• 81971-38-2 3-bromo-1-methyl-1H-pyridin-2-one 
• 81971-39-3 5-bromo-1-methylpyridin-2(1H)-one 
• 625-92-3 3,5-dibromopyridine 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 910543-72-5 3-amino-5-bromo-1-methyl-2H-pyridin-2-one 
• 1034583-90-8 5-bromo-3-(5-tert-butyl-1H-pyrazol-3-ylamino)-1-methyl-1H-pyridin-2-one 
• 1346672-61-4 5-bromo-1-methyl-3-(pyrimidin-4-ylamino)pyridin-2(1H)-one 
• 1346674-57-4 tert-butyl 4-(6-((5-bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)amino)pyridin-3-yl) piperazine-1-carboxylate 
• 1346672-60-3 1-methyl-3-(pyrimidin-4-ylamino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2(1H)-one 
• 1346669-97-3 2-(3-(5-(5-fluoropyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(hydroxymethyl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 
• 1346673-64-0 2-(5-(5-fluoropyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-6-(1-oxo-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-2(1H)-yl)benzyl acetate 
• 1346670-16-3 10-[2-(hydroxymethyl)-3-[1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydropyridin-3-yl]phenyl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.0(2,6)]dodeca-2⁽⁶⁾,7-dien-9-one 
• 1346674-25-6 10-[2-(acetoxymethyl)-3-[1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydropyridin-3-yl]phenyl]-4,4-dimethyl-1,10-diazatricyclo[6.4.0.0(2,6)]dodeca-⁽⁶⁾,7-dien-9-one 
• 1346670-08-3 2-(2-(hydroxymethyl)-3-(1-methyl-6-oxo-5-(pyrimidin-4-ylamino)-1,6-dihydropyridin-3-yl)phenyl)-3,4,6,7,8,9-hexahydropyrido[3,4-b]imidazo[4,5-c]pyridine-1-one 
• 1346670-04-9 5,5,6,6,7,7-hexadeutero-2-(2-(hydroxymethyl)-3-(1-methyl-5-(5-(1-methylazetidin-3-yl)pyridin-2-ylamino)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-3,4,5,6,7,8-hexahydrobenzothieno[2,3-c]pyridin-1(2H)-one 
• 1346673-88-8 2-(3-(5-(5-(azetidin-3-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(hydroxymethyl)phenyl)-5,5,6,6,7,7-hexadeutero-3,4,5,6,7,8-hexahydrobenzothieno[2,3-c]pyridin-1(2H)-one 
• 1346673-87-7 2-(5-(5-(azetidin-3-yl)pyridin-2-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-6-(5,5,6,6,7,7-hexadeutero-1-oxo-3,4,5,6,7,8-hexahydrobenzothieno[2,3-c]pyridin-2(1H)-yl)benzyl acetate 
• 1346669-91-7 2-(3-(5-(1,5-dimethyl-1H-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-(hydroxymethyl)phenyl)-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1(2H)-one 

Relevant academic research and scientific papers

Iridium-Catalysed C-H Borylation of 2-Pyridones; Bisfunctionalisation of CC4

The high regioselectivity associated with the iridium-catalysed borylation of pyridones has been exploited to provide a very direct and efficient entry to C(10) doubly substituted CC4 variants of cytisine. Two approaches have been evaluated based on (i) C-H activation of cytisine (or an N-substituted derivative) followed by N-alkylation (to enable dimer formation) and (ii) direct C-H activation and borylation of CC4 itself. Both approaches provide access to C(10)-functionalized CC4 derivatives, but direct borylation of CC4 allows for a wider range of functional group interconversions to be tolerated.

Development of an Efficient Manufacturing Process for Reversible Bruton's Tyrosine Kinase Inhibitor GDC-0853

Efforts toward the process development of reversible Bruton's tyrosine kinase (BTK) inhibitor GDC-0853 (1) are described. A practical synthesis of GDC-0853 was accomplished via a key highly regioselective Pd-catalyzed C-N coupling of tricyclic lactam 5 with 2,4-dichloronicotinaldehyde (6) to afford the C-N coupling product 3, a Suzuki-Miyaura cross-coupling of intermediate 3 with boronic ester 4 derived from a Pd-catalyzed borylation of tetracyclic bromide 7, to generate penultimate aldehyde intermediate 2 and subsequent aldehyde reduction and recrystallization. Process development of starting materials 5, 6, and 7 is also discussed.

PROCESS FOR PREPARING BTK INHIBITORS

Methods for preparing the Bruton's Tyrosine Kinase ("BTK") inhibitor compound 2- {3'-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2- ylamino]-6-oxo-1,6-dihydro-[3,4']bipyridinyl-2'-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H- cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one are provided. Methods for preparing tricyclic lactam compounds are also provided.

SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS

This application relates to substituted benzimidazoles of formula (I), compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. For example, the application relates to substituted benzimidazoles and to their use as bromodomain inhibitors. The present application also relates to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasm, including tumors and/or cancers.

An expeditious copper-catalyzed access to 3-aminoquinolinones, 3-aminocoumarins and anilines using sodium azide

An efficient copper-catalyzedin in situ C-(sp2)-NH2 bond formation to provide a range of 3-aminoquinolin-2(1H)-ones and 3-aminocoumarins from 3-bromoquinolinones and 3-bromocoumarins, respectively, has been achieved. The reaction conditions involve the use of copper powder as the catalyst, eco-friendly ethanol as the solvent in the pres ence of pipecolinic acid as the ligand and ascorbic acid as the additive. The efficiency of this practical method was demonstrated in the synthesis of various anilines.

Certain Substituted Amides, Method of Making, and Method of Use Thereof

At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS

Methods of inhibiting BTK activity by inhibiting phosphorylation of Y551 of BTK, methods of treating patients by inhibiting BTK activity by inhibiting phosphorylation of Y551 of BTK, chemical entities that bind to BTK and inhibited complexes are provided.

CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF

At least one chemical entity chosen from compounds of Formula (1) and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one ch

Kinetics and Mechanism of Bromination of 2-Pyridone and Related Derivatives in Aqueous Solution

The tautomeric system 2-pyridone 2-hydroxypyridine (1a 2a) reacts with aqueous bromine via the principal tautomer 1a at pH 6.Attack upon 1a occurs preferentially at the 3 position, whereas reaction upon the anion probably involves major attack at the 5 position.The facile dibromination of 2-pyridone results from the comparable reactivity of the monobromopyridones at pH 4.These conclusions are based upon kinetic and product studies of the bromination of 1a and various derivatives in aqueous solutions at pH 0-8.With respect to their reactivity toward bromine the pyridones behave as substituted phenoxide ions.

BROMINATION OF 1-ALKYL-2-PYRIDONES

The corresponding monobromides were obtained in the bromination of 1-alkyl-2-pyridones with bonded bromine (with N-bromosuccinimide and dioxane dibromide).The conditions under which the yields of the mixtures of isomers were 60-80percent, and almost no dibromides were obtained, were found.It was established that the ratios of the 3- and 5-bromo isomers depend on the character of the brominating agent.